EUROAPI has received official notification from the European Commission that the company has been selected as one of the 13 companies eligible to share up to €1 billion in total public funding under the Important Project of Common European Interest (IPCEI) dedicated to the pharmaceutical sector, “IPCEI Med4Cure.”

This IPCEI had been jointly notified by six member states of the European Union (EU)—France, Belgium, Hungary, Italy, Slovakia and Spain—as a means to strengthen the European health market and to ensure, in particular, sustainable, competitive and integrated production of active pharmaceutical ingredients (APIs) that are essential for public health. Under this program, the six member states are authorized by the EU to devote up to €1 billion in public funds for all selected projects and associated partners. The French government and EUROAPI will now be able to begin discussions to prepare the contractual agreement for the granting of public aid within the framework of France 2030.

Med4Cure will notably enable to co-fund EUROAPI’s R&D activities up to industrial feasibility studies. EUROAPI will leverage this IPCEI opportunity to further develop three programs and sustainable production processes in Europe and to help meet by 2030 the demand for critical medicines that are currently imported and offer new drug delivery solutions in the following sectors:

• For macrolide antibiotics used in the treatment of infectious diseases, EUROAPI’s project to reshore production at its Saint-Aubin-lès-Elbeuf site (Seine-Maritime) would enable the company to expand its portfolio in this global market.
• For corticosteroids (including methylprednisolone), which are used for their anti-inflammatory and immunosuppressive effects, EUROAPI intends to develop state-of-the-art processes and technologies at its Vertolaye site (Puy-de-Dôme).
• For nanoparticles, also in Vertolaye, EUROAPI’s objective is to increase the bioavailability of molecules in the body and to find new therapeutic applications for active pharmaceutical ingredients that already marketed, or to support the development of new drugs thanks to additional formulations.

“We are proud to have been selected by the European Commission. It is a true recognition of our mission and excellence in R&D. It will help us carry out innovative projects that are key to long-term European sovereignty and which will contribute to the green transition of the pharmaceutical industry,” said Ludwig de Mot, CEO, EUROAPI. “Our projects are built on strong collaborations with many valuable partners from the academic and start-up environments, allowing this European ecosystem to benefit from a spillover effect that will contribute to Europe’s competitiveness.”

The company says these three IPCEI programs are aligned with the company’s FOCUS-27 plan, which was launched in February 2024, and will help the it in building a more sustainable and profitable growth, in particular regarding corticosteroids.

For further information on this program, please refer to the European Commission press release.